Liver metastases and peritoneal metastases and response to checkpoint inhibitors in metastatic colorectal cancer with microsatellite instability

The Oncologist, Journal Year: 2024, Volume and Issue: 29(12), P. 1052 - 1058

Published: Sept. 25, 2024

There have been conflicting reports on the predictive impact of metastatic disease sites response to checkpoint inhibitors (CPI) in microsatellite instability (MSI) colorectal cancers (mCRC). Recent studies highlighted peritoneal metastases, ascites, and liver metastases as possible indicators resistance CPI.

Language: Английский

---

Immune Checkpoint Inhibitor Combined with Antiangiogenic Agent Synergistically Improving the Treatment Efficacy for Solid Tumors

ImmunoTargets and Therapy, Journal Year: 2024, Volume and Issue: Volume 13, P. 813 - 829

Published: Dec. 1, 2024

Language: Английский

---

Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trial

Cancer Imaging, Journal Year: 2024, Volume and Issue: 24(1)

Published: June 17, 2024

Abstract Background The Response Evaluation Criteria in Solid Tumors (RECIST) are often inadequate for the early assessment of response to cancer therapy, particularly bevacizumab-based chemotherapy. In a first cohort patients with colorectal liver metastases (CRLM), we showed that variations tumor-to-liver density (TTLD) ratio and modified size-based criteria determined using computed tomography (CT) data at restaging were better prognostic than RECIST. aims this study confirm relevance these radiological biomarkers as predictors long-term clinical outcome assess their correlation contrast-enhanced ultrasound (CEUS) parameters new patient cohort. Methods post-hoc multicenter STIC-AVASTIN trial, retrospectively reviewed CT CRLM treated regimens. We size, TTLD target lesions baseline also performed morphologic evaluation according MD Anderson criteria. assessed progression-free survival (PFS) overall (OS) log-rank test Cox proportional hazard model. examined association between quantitative CEUS parameters. Results This analysis concerned 79 137 included trial. PFS OS significantly longer tumor size reduction > 15% restaging, but not correlated variations. However, was 0.6 those who did reach threshold. multivariate analysis, only significant predictor. associated improved perfusion Conclusions Although correlate outcomes, absolute values remained good predictor may reflect microvascular features might influence treatment efficiency. Trial registration NCT00489697, number

Language: Английский

---

SHR-8068 combined with adebrelimab and bevacizumab in the treatment of refractory advanced colorectal cancer: study protocol for a single-arm, phase Ib/II study

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 9, 2024

The third-line treatment for refractory colorectal cancer (CRC) has limited efficacy. This study aimed to evaluate the safety and efficacy of SHR-8068 (an anti-CTLA-4 antibody), combined with adebrelimab anti-PD-L1 bevacizumab in non-microsatellite instability-high (MSI-H) or proficient mismatch repair (pMMR) CRC.

Language: Английский

---

Updated Survival Outcome of Regorafenib, Ipilimumab, and Nivolumab in Refractory Microsatellite Stable Non-Liver Metastatic Colorectal Cancer: A Phase I Nonrandomized Clinical Trial

European Journal of Cancer, Journal Year: 2024, Volume and Issue: 213, P. 115111 - 115111

Published: Nov. 2, 2024

Language: Английский

---